BEST of ASCO Portugal 2024 - Esophagogastric and Hepatobiliopancreatic Tumors
Resumo
Na reunião anual da ASCO 2024, que teve lugar em Chicago, de 31 de janeiro a 4 de fevereiro de 2024, foram apresentados trabalhos muito relevantes nas mais diversas áreas da Oncologia.
No que respeita aos trabalhos desenvolvidos em tumores esofagogástricos e hepatobilipancreáticos, foram selecionados 3 ensaios clínicos, pelo seu possível impacto na prática clínica diária, para serem apresentados e discutidos, em Coimbra, no dia 5 de julho, no BEST OF ASCO PORTUGAL 2024, organizado pela Sociedade Portuguesa de Oncologia.
Downloads
Referências
Al-Batran S-E, Homann N, Pauligk C et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11.
Shapiro J, van Lanschot J , Hulshof M et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015 Sep;16(9):1090-1098. doi: 10.1016/S1470-2045(15)00040-6. Epub 2015 Aug 5.
Kelly R, Ajani J, Kuzdzal J et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med 2021; 384:1191-1203. DOI: 10.1056/NEJMoa2032125.
Janjigian Y, Van Cutsem E, Muro K et al. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. Future Oncol. 2022 Jun;18(20):2465-2473. doi: 10.2217/fon-2022-0093.
Shitara K, Rha S, Wyrwicz L et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol 2024 Feb;25(2):212-224. doi: 10.1016/S1470-2045(23)00541-7.
Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med 2011;364: 1817-1825.DOI: 10.1056/NEJMoa1011923.
Wainberg Z, Melisi D, Macarulla T et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023 Oct 7;402(10409):1272-1281. doi: 10.1016/S0140-6736(23)01366-1.
Goldstein D, El-Maraghi R, Hammel P et al. Nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015 Jan 31;107(2): dju413. doi: 10.1093/jnci/dju413.
Finn R, Qin S, Ikeda M et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020; 382:1894-1905. DOI: 10.1056/NEJMoa1915745.
Abou-Alfa G, Lau G, Kudo M et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid. 2022 Aug;1(8): EVIDoa2100070. doi: 10.1056/EVIDoa2100070.
Qin S , Chan S , Gu S et al . Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3.
